# TRUDI (NCT05795101)

> TRUDI: TDXD+Durva in HER2+/Low IBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05795101
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Filipa Lynce, MD
- Conditions: Invasive Breast Cancer; Inflammatory Breast Cancer Stage III; HER2-positive Breast Cancer; HER2 Low Breast Adenocarcinoma; Breast Cancer
- Interventions: Trastuzumab deruxtecan; Durvalumab
- Enrollment: 63
- Primary outcome: Pathological complete response (pCR) Rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9
- YouTube: 2
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=trudi-nct05795101

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05795101", "email": "<work email>"}; the inbox owner confirms by the emailed link.